Overview

Dr. Talapatra is a partner and intellectual property lawyer with Foley & Lardner LLP. Dr. Talapatra’s practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. Dr. Talapatra also has a unique perspective on European companies with ties of the U.S., having lived in The Netherlands and frequently returning to the continent.  In addition to patent counseling and prosecution matters, he has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the "1st-Ever" Pharma AIA Ruling (Amneal Pharma Inc v. Supernus Pharma Inc.). Some of Dr. Talapatra's exemplary patent cases include Chatterjee v Tabor (interference proceeding re DNA polymerase); Keygene NV vs Floragenex, Inc. (patent infringement action) and Biota Scientific Ltd. vs Kappos (appeal of USPTO decision re obviousness of pharmaceutical formulation). He is a member of the Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Life Sciences Industry Team.

Thought Leadership

Dr. Talapatra has authored several legal and scientific publications and is frequently quoted in FDA Week and Inside Health Policy. He also regularly lectures on patent matters, most recently at the 2016 FCBA Global Outreach Series (Paris).

Education

Dr. Talapatra earned his law degree from The George Washington University. He received his Ph.D. in cell and molecular biology from the University of Pennsylvania. He also holds an M.S. in biochemistry and molecular biology from the University of Chicago and a B.S. in chemistry from the University of California at Los Angeles. Dr. Talapatra’s graduate work in cancer biology was conducted under the guidance of Dr. Craig Thompson.

Admissions

Dr. Talapatra is admitted to practice in Virginia and the District of Columbia and before the United States Patent and Trademark Office.

Select Speaking Engagements

  • "Patenting Strategies: The Counsel (Corporate and Private),” FCBA Global Outreach Series (October 2016)
  • "IP Management: Getting It Right in Both Europe and the US," Innovation for Health Conference (February 2014)
  • "Legal Issues Facing Health Companies in the US Market," Health & Technology Conference (September 2013)
  • "Hindsight is 20/20: Entrepreneurs Share Viewpoints on What They Wish They'd Known," Nanotech Commercialization Conference (April, 2013)
  • "Intellectual Property," Wharton Business Law Conference (February, 2013)
  • "Intellectual Property Life Cycle Management—Thoughts to Consider in Strategic Patent Protection," American Chemical Society (August, 2012)
  • "Risk vs Value: The Impact of Nanotechnology Environmental Health Safety (EHS) on Business Decisions," Nanotech Commercialization Conference (April, 2012)
  • "What's 'natural' about natural resources? Implications for your IP," American Chemical Society (March, 2011)
  • "Negotiating a patent: the art of Examiner interviews," American Chemical Society (August, 2010)

Select Publications

  • Talapatra S, Bent S, The Art of Negotiating with U.S. Patent Examiners, A.I.P.P.I. 56(2), 2011
  • Talapatra S, Thompson CB, et al., Elongation Factor-1 alpha Is a Selective Regulator of Growth Factor Withdrawal and ER Stress- induced Apoptosis, Cell Death Differ., 9(8), 2002, 856-61
  • Karnauskas R, Talapatra S, and Rudin C, et al., Bcl-xL and Akt Cooperate to Promote Leukemogenesis In Vivo, Oncogene, 22(5), 2003, 688-98

Representative Matters

Showing of
The prosecution of the subject application had stalled after years of effort before the U.S. PTO. In close consultation with in-house counsel, Foley planned and implemented an initiative, including a major PTO meeting including representatives from all parties, that broke the case open and resulted in the allowance noted above.